For some pancreatic cancers with actionable mutations, such as germline BRCA1/2 mutations, NTRK fusion mutation, and MSI-H, molecular-targeted therapy and immunotherapy are being introduced. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.